| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
HA Peptide targets the HA tag epitope, specifically binding to anti-HA antibodies. It does not have a biological target but is used as an affinity tag for protein purification and detection. Excessive addition of this peptide enables competitive elution of HA tag fusion proteins from anti-HA antibody affinity columns.
|
|---|---|
| ln Vitro |
In addition to being a useful tool for co-immunoprecipitation, the highly immunoreactive HA peptide is also readily detected by Western blotting. It is frequently used to separate tagged proteins from cell culture supernatants and cell lysates at neutral pH. Because HA peptides are tiny, it is unlikely that they will affect the fusion partner protein's biological activity or functionality. Since HA peptide is a highly immunoreactive epitope, it can be utilized extensively for target protein extraction, purification, detection, and tracking. It is generated from human influenza hemagglutinin (HA), which corresponds to amino acids 98–106. Highly specific anti-HA monoclonal antibodies covalently immobilized on resin can be used to isolate recombinant HA-tagged proteins. A mild elution technique can be used to elute HA-tagged proteins, using a HA epitope concentration of 1 mg/mL in TBS. However, three chemical elution alternatives are available: 50 mM NaOH, 3 M NaSCN, or 0.1 M Glycine (pH 2-2.8)[1]. T7 promoter-driven expression in E requires the nucleotide sequence in the mammalian expression vector that codes for the N-terminal HA peptide. coli, even in the event when trans-acting T7 RNAP is absent [2]. These results show that caspase 3/7 cleaves the HA peptide, which leads to total loss of immunological reactivity. There may be serious artifacts when employing HA to identify proteins and structures in order to investigate apoptotic and cell death-related processes, according to observations [3].
In vitro, HA Peptide is used for antibody affinity purification of HA tag fusion proteins. It is added in excess to competitively elute HA tag fusion proteins from anti-HA antibody affinity columns. It is also used in immunoprecipitation and Western blotting applications. |
| ln Vivo |
In vivo, HA Peptide is not used as a therapeutic agent. Its applications are strictly in vitro, for protein purification, detection, and tracking in cell biology and biochemistry.
|
| Enzyme Assay |
The in vitro affinity purification protocol for HA Peptide involves loading a cell lysate containing HA-tagged proteins onto an anti-HA antibody affinity column. The column is washed, and the HA Peptide is added in excess to competitively elute the bound HA-tagged proteins. The eluted proteins are collected and analyzed.
|
| Cell Assay |
In vitro cell culture studies for HA Peptide are not typically performed, as it is a peptide tag used for protein detection and purification. However, cells expressing HA-tagged proteins can be lysed, and the HA Peptide can be used to detect or purify the tagged proteins.
|
| ADME/Pharmacokinetics |
HA Peptide has a molecular weight of 1102.18 g/mol and a purity of ≥95%. It is typically stored as a powder at -20°C. It is soluble in aqueous buffers.
|
| Toxicity/Toxicokinetics |
HA Peptide is considered to have low toxicity, as it is a short peptide used in laboratory applications. As a research reagent, it is not intended for human use. Standard safety precautions for handling peptides should be followed.
|
| References |
|
| Additional Infomation |
HA peptide is a nine-amino acid peptide with the sequence YPYDVPDYA, derived from an epitope of the influenza virus hemagglutinin protein. It is widely used as an epitope tag for recombinant proteins to facilitate their isolation, purification, and detection.
HA Peptide is a widely used research reagent with no clinical approval. It is a standard tool for protein purification, detection, and tracking in cell biology and biochemistry. It is used in immunoprecipitation, Western blotting, and affinity chromatography applications. |
| Molecular Formula |
C53H67N9O17
|
|---|---|
| Molecular Weight |
1102.14918
|
| Exact Mass |
1101.47
|
| CAS # |
92000-76-5
|
| Related CAS # |
HA Peptide TFA
|
| PubChem CID |
10235423
|
| Appearance |
White to off-white solid powder
|
| Density |
1.414±0.06 g/cm3 (20ºC 760 Torr)
|
| LogP |
1.68
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
79
|
| Complexity |
2180
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N
|
| InChi Key |
HVLSXIKZNLPZJJ-TXZCQADKSA-N
|
| InChi Code |
InChI=1S/C53H67N9O17/c1-27(2)44(52(77)62-21-5-7-41(62)50(75)59-38(25-42(66)67)47(72)56-36(45(70)55-28(3)53(78)79)23-30-10-16-33(64)17-11-30)60-48(73)39(26-43(68)69)57-46(71)37(24-31-12-18-34(65)19-13-31)58-49(74)40-6-4-20-61(40)51(76)35(54)22-29-8-14-32(63)15-9-29/h8-19,27-28,35-41,44,63-65H,4-7,20-26,54H2,1-3H3,(H,55,70)(H,56,72)(H,57,71)(H,58,74)(H,59,75)(H,60,73)(H,66,67)(H,68,69)(H,78,79)/t28-,35-,36-,37-,38-,39-,40-,41-,44-/m0/s1
|
| Chemical Name |
(3S)-3-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~33.33 mg/mL (~30.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9073 mL | 4.5366 mL | 9.0732 mL | |
| 5 mM | 0.1815 mL | 0.9073 mL | 1.8146 mL | |
| 10 mM | 0.0907 mL | 0.4537 mL | 0.9073 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
